AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, monobactam/beta-lactamase inhibitor combination antibiotic.
Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic macular edema with fewer treatments based on its continuous delivery of a customized formulation ...
TUESDAY, Feb. 4, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved the first-ever clinical ...
Supernus (SUPN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, approved ONAPGO injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine ...
Vertex sees 2025 revenue of $11.75 billion to $12.0 billion, the midpoint of which is above analysts' average expectation of ...
Milla Blake in "Apple Cider Vinegar" shares similarities with Australian wellness influencer Jess Ainscough, who died in 2015 ...
Lilly Chief Financial Officer Lucas Montarce told Reuters last month the drugmaker is trying to balance its demand-generation activities with its ability to supply more patients. The company last year ...
AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.
Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...
GlobalData on MSN18h
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback